Comparable levels of CD4+ and CD8+ T-cells were seen as in the earlier phase I trials, but the vaccine regimen was unable to decrease total viral shedding, symptom score, or the incidence of influenza-like illness after infection (183). Here, CD8A is linked to influenza.